Merck制造部门负责人Dave Maraldo谈生物制品与ADC产能布局的3项原则
What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?
Merck制造部门执行副总裁兼总裁Dave Maraldo提出指导产能布局的3项原则:贴近所服务患者与市场的地理布局、同类技术共址集中,以及在有机会时推进协调统一。他以特拉华州Wilmington生物制品生产将建成卓越中心为例说明共址思路。Maraldo将端到端ADC供应链列为未来可能实现产能协调的设想,而非公司当前计划。
Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
Dave Maraldo, PhD, executive vice president and president of the Merck Manufacturing Division, discusses how Merck decides where to place new manufacturing capacity in an interview with BioPharm International®. He explains that biologics, antibody-drug conjugates (ADCs), and other complex modalities increasingly blur together on the same platforms, which complicates those decisions.
Dr Maraldo posits an end-to-end ADC supply chain as a future potential example of capacity harmonization. In an ADC supply chain, the drug linker is a small molecule process, while the monoclonal antibody and drug conjugation steps are more biologically inclined.
Dr Maraldo says Merck's manufacturing network design relative to technology rests on 3 principles, which, together, shape how Merck places capacity for each technology. The first principle is geographic placement relative to the patients and the markets the company serves. The second is co-localization of like technologies. He cites biologics manufacturing in Wilmington, Delaware, which is set to become a center of excellence, so Merck can build the requisite knowledge base, achieve economies of scale, and put like things together as it configures the network.1 Merck operates vaccines, biologics, and small molecule plants. The third principle is harmonization, which Merck will pursue wherever an opportunity exists, according to Dr. Maraldo.
How could end-to-end ADC supply chains change manufacturing investment?
Dr Maraldo posits an end-to-end ADC supply chain as a future potential example of capacity harmonization. In an ADC supply chain, the drug linker is a small molecule process, while the monoclonal antibody and drug conjugation steps are more biologically inclined. A sterile filling operation then persists across all 3 modalities, he says.
An investment in such a chain may push companies past the traditional choice of building for a modality and toward building for a platform or a product family, he explains. "I think that's the maturing that's happening, at least in my way of thinking, as we move through some of these more complex molecules," Dr Maraldo notes.
He also states that a time may come when Merck recognizes the opportunity or chooses to invest in such a chain. He frames this notion as a possible future scenario rather than a current plan for the company.
To gain more insight on Merck, watch an exclusive interview with Dr Maraldo on Pharmaceutical Executive, a sister publication to BioPharm International under MJH Life Sciences.
Reference
- Merck. Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware. Press release. Published April 29, 2025. Accessed November 12, 2026. https://www.merck.com/news/merck-breaks-ground-on-new-1-billion-biologics-center-of-excellence-in-wilmington-delaware/
About the speaker
Dave Maraldo, PhD, Executive Vice President and President, Merck Manufacturing Division
Dr Maraldo has responsibility for Merck’s worldwide human health manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines and biologics. Since joining the company as a project engineer in 1999, he progressed through a range of leadership roles across manufacturing, technical operations, commercialization, and integrated development and supply. Building on that foundation, he led global biologics operations from 2022-2025 and most recently served as senior vice president of human health manufacturing. Dr Maraldo earned his PhD and master of chemical engineering degrees from Drexel University, an MBA degree from Lehigh University, and a bachelor of chemical engineering degree from Widener University.
Related to this article
November 13th, 2026
Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
November 13th, 2026
A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.
November 10th, 2026
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
November 9th, 2026
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
November 5th, 2026
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
November 12th, 2026
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
November 12th, 2026
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
November 12th, 2026
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
来源:BioPharm International · biopharminternational.com







